CA Patent

CA3231695A1 — Modified short interfering nucleic acid (sina) molecules and uses thereof

Assigned to Aligos Therapeutics Inc · Expires 2023-03-16 · 3y expired

What this patent protects

Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.

USPTO Abstract

Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.

Drugs covered by this patent

plozasiran-sodium (PLOZASIRAN SODIUM)

Patent Metadata

Patent number: CA3231695A1
Jurisdiction: CA
Classification: —
Expires: 2023-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Aligos Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.